PTD-DBM — a peptide studied for hair regrowth, wound healing, and scarless skin repair via Wnt/β-catenin activation.
PTD-DBM is a synthetic peptide built around a Dishevelled-binding motif (DBM) fused to a protein transduction domain (PTD) that lets it cross cell membranes. Once inside the cell, it blocks the interaction between a regulatory protein called CXXC5 and Dishevelled, a key relay in the Wnt/β-catenin signaling pathway. Wnt/β-catenin is one of the body's master switches for tissue regeneration — it tells stem cells to divide, hair follicles to enter the growth phase, and skin to rebuild itself after injury.
CXXC5 acts as a brake on that pathway. By disrupting the CXXC5-Dishevelled connection, PTD-DBM effectively releases the brake, allowing β-catenin to activate genes involved in regeneration. This makes the peptide an interesting tool for two areas where Wnt signaling matters most: hair follicle biology and skin wound repair. Researchers have explored it both alone and in combination with valproic acid, a GSK3β inhibitor that activates the same pathway from a different angle, with the two agents producing additive effects.
What sets PTD-DBM apart from broader Wnt activators is its specificity. Rather than turning the entire pathway on globally — which can have unwanted consequences — it targets a single negative regulator that's elevated in damaged or hair-loss-prone tissue.
1 vendor carries PTD-DBM.
Compare prices →Androgenetic alopecia — the most common form of hair loss in both men and women — has long been linked to dihydrotestosterone (DHT), but the downstream mechanism has remained incompletely understood. A 2023 study mapped out a DHT-PGD2-CXXC5 axis, showing that DHT drives production of prostaglandin D2 (PGD2), which in turn elevates CXXC5, which suppresses the Wnt/β-catenin signaling that hair follicles need to enter and sustain the growth phase (1).
PTD-DBM was tested as a way to interrupt this cascade at its final step. Treatment restored hair growth that had been suppressed by PGD2 and overcame the blockade of neogenic hair formation in a wound-induced hair neogenesis model — a system where new follicles form spontaneously during skin healing (1). Genetic removal of CXXC5 produced similar effects, confirming that the peptide's benefit comes specifically from disrupting CXXC5 function rather than from off-target activity.
The practical implication is that PTD-DBM may address a step in hair loss that current treatments don't directly target. Finasteride works upstream by blocking DHT production; minoxidil works through vascular and follicular effects with an unclear mechanism. PTD-DBM works downstream of DHT, at the point where the hair follicle's own regenerative signaling has been silenced, suggesting it could complement rather than duplicate existing approaches.
The peptide's wound-healing properties were actually identified before its hair effects. A 2015 study established CXXC5 as a negative feedback regulator of cutaneous wound repair and showed that PTD-DBM disrupts this brake to activate β-catenin and collagen production in skin cells (3). When applied to wounds in combination with valproic acid, the two agents synergistically accelerated healing, with faster wound closure and improved tissue reconstruction compared to either treatment alone.
The mechanism centers on the regenerative signaling that fetal skin uses to heal without scarring — a capacity adult skin largely loses. By reactivating Wnt/β-catenin, PTD-DBM appears to nudge adult wound healing back toward that more regenerative pattern (3).
Building on the wound-healing work, a 2023 study delivered PTD-DBM through pyrogallol-functionalized hyaluronic acid (HA-PG) adhesive patches — a hydrogel system designed to keep the peptide localized at the wound site over time (2). The patches were loaded with PTD-DBM alone or in combination with valproic acid, and the results pointed toward genuine regenerative healing rather than the typical fibrotic scar response.
Treated wounds showed reduced expression of α-smooth muscle actin (α-SMA), a marker of the myofibroblasts that drive scar tissue formation, while showing increased expression of stem cell markers like CD105 and Nestin (2). Collagen III, a flexible collagen type associated with fetal-style regenerative healing rather than the rigid Collagen I that dominates adult scars, was significantly upregulated.
Taken together, the wound and scar studies suggest PTD-DBM may shift the skin's response to injury away from the default adult pattern — fast closure with permanent scarring — and toward something closer to true tissue regeneration. The combination with delivery technologies like adhesive hydrogels addresses the practical challenge of keeping a peptide active at a wound site long enough to influence the multi-day healing process.
Reported side effects in the published research are minimal — the studies available describe PTD-DBM as well-tolerated in the laboratory settings tested, with no significant adverse effects noted (1, 2, 3). Because the peptide acts on Wnt/β-catenin signaling, a pathway involved in cell proliferation broadly, long-term and systemic safety is an area researchers continue to examine, particularly with extended or non-localized exposure.
Most of the work to date has used topical or wound-localized delivery rather than systemic administration, which limits direct comparison to peptides given by injection. The body of PTD-DBM evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.